Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Total Debt (2016 - 2025)

Immucell (ICCC) has disclosed Total Debt for 16 consecutive years, with $9.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Debt fell 12.95% year-over-year to $9.5 million, compared with a TTM value of $9.5 million through Sep 2025, down 12.95%, and an annual FY2024 reading of $10.5 million, down 11.95% over the prior year.
  • Total Debt was $9.5 million for Q3 2025 at Immucell, down from $9.8 million in the prior quarter.
  • Across five years, Total Debt topped out at $12.3 million in Q3 2023 and bottomed at $9.1 million in Q2 2021.
  • Average Total Debt over 5 years is $10.2 million, with a median of $10.2 million recorded in 2024.
  • The sharpest move saw Total Debt rose 17.55% in 2023, then dropped 12.95% in 2025.
  • Year by year, Total Debt stood at $9.1 million in 2021, then increased by 11.94% to $10.2 million in 2022, then rose by 17.0% to $12.0 million in 2023, then fell by 11.95% to $10.5 million in 2024, then fell by 9.94% to $9.5 million in 2025.
  • Business Quant data shows Total Debt for ICCC at $9.5 million in Q3 2025, $9.8 million in Q2 2025, and $10.2 million in Q1 2025.